中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 1
Jan.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(1): 29-32

Establishment and application of animal models for portal vein thrombosis

DOI: 10.12449/JCH240105
  • 1.

    Department of Gastroenterology，General Hospital of Northern Theater Command，Shenyang 110840，China

  • 2.

    Graduate School of China Medical University，Shenyang 110122，China

  • 3.

    Graduate School，Dalian Medical University，Dalian，Liaoning 116044，China

  • 4.

    Department of Gastroenterology，Affiliated Drum Tower Hospital of Nanjing University Medical School，Nanjing 210008，China

Research funding:

National Natural Science Foundation of China (8227034094)

More Information
  • Corresponding author: QI Xingshun， xingshunqi@126.com （ORCID： 0000-0002-9448-6739）
  • Received Date: 2023-11-22
  • Accepted Date: 2023-11-30
  • Published Date: 2024-01-23
    Abstract
  • Portal vein thrombosis （PVT） refers to thromboembolism that occurs in the extrahepatic main portal vein and/or intrahepatic portal vein branches. PVT is the result of the combined effect of multiple factors， but its pathogenesis remains unclear. Animal models are an important method for exploring the pathophysiological mechanism of PVT. Based on the different species of animals， this article reviews the existing animal models of PVT in terms of modeling methods， principles， advantages and disadvantages， and application.

     

    • FullText(HTML)
  • loading
    • References(38)
  • [1]
    QI X. Portal vein thrombosis: Recent advance[J]. Adv Exp Med Biol, 2017, 906: 229- 239. DOI: 10.1007/5584_2016_118.
    [2]
    OGREN M, BERGQVIST D, BJÖRCK M, et al. Portal vein thrombosis: Prevalence, patient characteristics and lifetime risk: A population study based on 23, 796 consecutive autopsies[J]. World J Gastroenterol, 2006, 12( 13): 2115- 2119. DOI: 10.3748/wjg.v12.i13.2115.
    [3]
    PAN JH, WANG L, GAO FB, et al. Epidemiology of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis[J]. Eur J Intern Med, 2022, 104: 21- 32. DOI: 10.1016/j.ejim.2022.05.032.
    [4]
    TRIPODI A, MANNUCCI PM. The coagulopathy of chronic liver disease[J]. N Engl J Med, 2011, 365( 2): 147- 156. DOI: 10.1056/NEJMra1011170.
    [5]
    INTAGLIATA NM, CALDWELL SH, TRIPODI A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis[J]. Gastroenterology, 2019, 156( 6): 1582- 1599.e1. DOI: 10.1053/j.gastro.2019.01.265.
    [6]
    QI XS, HAN GH, FAN DM. Research progress on portal vein occlusion[J]. Natl Med J China, 2014, 94( 6): 473- 475. DOI: 10.3760/cma.j.issn.0376-2491.2014.06.020.

    祁兴顺, 韩国宏, 樊代明. 门静脉阻塞研究进展[J]. 中华医学杂志, 2014, 94( 6): 473- 475. DOI: 10.3760/cma.j.issn.0376-2491.2014.06.020.
    [7]
    QI X, REN W, de STEFANO V, et al. Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: A systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2014, 12( 11): 1801- 1812. e 7. DOI: 10.1016/j.cgh.2014.04.026.
    [8]
    QI XS, de STEFANO V, WANG J, et al. Prevalence of inherited antithrombin, protein C, and protein S deficiencies in portal vein system thrombosis and Budd-Chiari syndrome: A systematic review and meta-analysis of observational studies[J]. J Gastroenterol Hepatol, 2013, 28( 3): 432- 442. DOI: 10.1111/jgh.12085.
    [9]
    ZOCCO MA, di STASIO E, de CRISTOFARO R, et al. Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis development[J]. J Hepatol, 2009, 51( 4): 682- 689. DOI: 10.1016/j.jhep.2009.03.013.
    [10]
    PATTERSON KA, ZHANG X, WROBLESKI SK, et al. Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects[J]. Thromb Res, 2013, 131( 3): 268- 276. DOI: 10.1016/j.thromres.2012.12.006.
    [11]
    WOJCIK BM, WROBLESKI SK, HAWLEY AE, et al. Interleukin-6: A potential target for post-thrombotic syndrome[J]. Ann Vasc Surg, 2011, 25( 2): 229- 239. DOI: 10.1016/j.avsg.2010.09.003.
    [12]
    SINGH I, BURNAND KG, COLLINS M, et al. Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: Rescue by normal bone marrow-derived cells[J]. Circulation, 2003, 107( 6): 869- 875. DOI: 10.1161/01.cir.0000050149.22928.39.
    [13]
    ANDIA ME, SAHA P, JENKINS J, et al. Fibrin-targeted magnetic resonance imaging allows in vivo quantification of thrombus fibrin content and identifies thrombi amenable for thrombolysis[J]. Arterioscler Thromb Vasc Biol, 2014, 34( 6): 1193- 1198. DOI: 10.1161/ATVBAHA.113.302931.
    [14]
    WEI YH, SHAO J, SHEN H, et al. The inhibitory role of recombinant P-selectin glycoprotein ligand immunoglobulin G on portal vein thrombosis based on a novel rat model[J]. Exp Ther Med, 2019, 17( 5): 3589- 3597. DOI: 10.3892/etm.2019.7394.
    [15]
    YAO LL, PAN WZ, GE LF, et al. Establishment and evaluation of rat model with portal vein thrombosis[J]. Sichuan J Anat, 2018, 26( 2): 1- 4. DOI: 10.3969/j.issn.1005-1457.2018.02.001.

    姚露露, 潘闻证, 葛立峰, 等. 门静脉血栓大鼠模型的建立及评价[J]. 四川解剖学杂志, 2018, 26( 2): 1- 4. DOI: 10.3969/j.issn.1005-1457.2018.02.001.
    [16]
    LI WW. Construction of a rat portal vein thrombosis model and observation of thrombus dynamics[D]. Chengde: Chengde Medical University, 2023. DOI: 10.27691/d.cnki.gcdyx.2023.000402.

    李威威. 大鼠门静脉血栓模型构建和血栓动态观察[D]. 承德: 承德医学院, 2023. DOI: 10.27691/d.cnki.gcdyx.2023.000402.
    [17]
    ZHANG JY, CHEN WX, SHEN H, et al. Establishment and observation of portal vein thrombosis model in rats[J]. Chin J Gen Surg, 2018, 27( 6): 724- 731. DOI: 10.3978/j.issn.1005-6947.2018.06.011.

    张津瑜, 陈文显, 沈华, 等. 大鼠门静脉系统血栓形成模型的建立和观察[J]. 中国普通外科杂志, 2018, 27( 6): 724- 731. DOI: 10.3978/j.issn.1005-6947.2018.06.011.
    [18]
    XU M, XUE WL, MA ZH, et al. Resveratrol reduces the incidence of portal vein system thrombosis after splenectomy in a rat fibrosis model[J]. Oxid Med Cell Longev, 2016, 2016: 7453849. DOI: 10.1155/2016/7453849.
    [19]
    OMOKAWA S, ASANUMA Y, KOYAMA K. Evaluation of hemodynamics and hepatic mitochondrial function on extrahepatic portal obstruction in the rat[J]. World J Surg, 1990, 14( 2): 247-253; discussion 253-254. DOI: 10.1007/BF01664884.
    [20]
    HE Q, ZHANG SB, ZHU F, et al. Influence of chronic biliary infection on coagulation status in portal vein system in rabbits[J]. Chin J Gen Surg, 2013, 22( 8): 1038- 1042.

    何谦, 张少波, 祝峰, 等. 慢性胆道感染对兔门静脉系统凝血环境的影响[J]. 中国普通外科杂志, 2013, 22( 8): 1038- 1042.
    [21]
    IDE T, OHNO Y, NAKANUMA Y, et al. Early development of cavernomatous vasculatures in portal venous thrombosis: Morphometric kinetics in rabbit model[J]. Hepatol Res, 2003, 27( 2): 136- 142. DOI: 10.1016/s1386-6346(03)00208-0.
    [22]
    ITOH K, IEKO M, HIRAGUCHI E, et al. In vivo kinetics of 99mTc labeled recombinant tissue plasminogen activator in rabbits[J]. Ann Nucl Med, 1994, 8( 3): 193- 199. DOI: 10.1007/BF03164997.
    [23]
    FENG YP, ZHANG FX, NIU LY, et al. Simvastatin ameliorates deep vein thrombosis in rabbits by regulating the fibrinolytic system[J]. Blood Coagul Fibrinolysis, 2016, 27( 5): 531- 541. DOI: 10.1097/MBC.0000000000000567.
    [24]
    KNIGHT LC, MAURER AH, AMMAR IA, et al. Tc-99m antifibrin Fab' fragments for imaging venous thrombi: Evaluation in a canine model[J]. Radiology, 1989, 173( 1): 163- 169. DOI: 10.1148/radiology.173.1.2781002.
    [25]
    KNIGHT LC, MAURER AH, ROMANO JE. Comparison of iodine-123-disintegrins for imaging thrombi and emboli in a canine model[J]. J Nucl Med, 1996, 37( 3): 476- 482.
    [26]
    LUO DY. Construction of a canine portal vein thrombosis model[D]. Hengyang: University of South China, 2020. DOI: 10.27234/d.cnki.gnhuu.2019.000715.

    罗东阳. 犬门静脉血栓模型的构建[D]. 衡阳: 南华大学, 2020. DOI: 10.27234/d.cnki.gnhuu.2019.000715.
    [27]
    DENG LM, DENG T, LUO DY, et al. A new modified canine model of portal vein thrombosis[J]. Acta Biochim Biophys Sin, 2021, 53( 2): 265- 268. DOI: 10.1093/abbs/gmaa165.
    [28]
    PENG CT. The effect of hepatocyte growth factor on the organized reperfusion of canine portal vein thrombosis through the JAK2-STAT3 signaling pathway[D]. Hengyang: University of South China, 2019.

    彭长铁. 肝细胞生长因子通过JAK2-STAT3信号通路对犬门静脉血栓机化再通的影响[D]. 衡阳: 南华大学, 2019.
    [29]
    SHI WY, WU S, HU LY, et al. Swine model of thrombotic caval occlusion created by autologous Thrombus injection with assistance of intra-caval net knitting[J]. Sci Rep, 2015, 5: 18546. DOI: 10.1038/srep18546.
    [30]
    ROBINSON VJB, PINEDA GE, SALAH AK, et al. Latex D-dimer signal in in situ femoral vein thrombus in swine and effect of minidose exogenous tissue plasminogen activator bolus[J]. Chest, 2005, 127( 2): 622- 629. DOI: 10.1378/chest.127.2.622.
    [31]
    GOLDBERG SN, AHMED M, WEINSTEIN J, et al. Low-power transverse ultrasonic treatment of portal vein thrombosis in an animal model[J]. J Vasc Interv Radiol, 2002, 13( 9 Pt 1): 915- 921. DOI: 10.1016/s1051-0443(07)61775-8.
    [32]
    ZHANG R, LU SX, JIANG YY, et al. A preclinical porcine model of portal vein thrombosis in liver cirrhosis[J]. Biomed Res Int, 2020, 2020: 3086906. DOI: 10.1155/2020/3086906.
    [33]
    LIU K, MENG JX, FAN XX, et al. Establishment of mesenteric venous thrombosis in a porcine model using a transhepatic endovascular approach[J]. Thromb Res, 2015, 136( 6): 1179- 1184. DOI: 10.1016/j.thromres.2015.10.028.
    [34]
    ZHU L. Experimental and clinical application research on interventional treatment of portal vein thrombosis[D]. Shanghai: Fudan University, 2011.

    朱樑. 介入途径治疗门静脉系统血栓的实验与临床应用研究[D]. 上海: 复旦大学, 2011.
    [35]
    ZHANG L, FU JX, SONG P, et al. The safety of Habib VesOpen bipolar radiofrequency ablation catheter used in the treatment of portal vein tumor thrombus:an experimental study in miniature pig models[J]. J Interv Radiol, 2015( 6): 515- 519. DOI: 10.3969/j.issn.1008-794X.2015.06.012.

    张林, 付金鑫, 宋鹏, 等. Habib VesOpen消融导管治疗小型猪模拟门静脉癌栓的安全性研究[J]. 介入放射学杂志, 2015( 6): 515- 519. DOI: 10.3969/j.issn.1008-794X.2015.06.012.
    [36]
    TIAN RY. Exploratory study on portal vein thrombosis and anticoagulant therapy in patients with liver cirrhosis[D]. Jinan: Shandong University, 2022.

    田瑞渊. 肝硬化门静脉血栓及抗凝治疗的探索性研究[D]. 济南: 山东大学, 2022.
    [37]
    NG KKC, LAM CM, POON RTP, et al. Delayed portal vein thrombosis after experimental radiofrequency ablation near the main portal vein[J]. Br J Surg, 2004, 91( 5): 632- 639. DOI: 10.1002/bjs.4500.
    [38]
    CAMPOS J, BRILL A. By word of mouse: Using animal models in venous thrombosis research[J]. Platelets, 2020, 31( 4): 447- 454. DOI: 10.1080/09537104.2019.1678117.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (453) PDF downloads(81) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return